Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 4/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.59 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSPO | P30536 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18286333 | 1.00 | SGPL1 (0.61) | SGPL1S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL43371 | 1.00 | SGPL1 (0.61) | SGPL1S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL20510812 | 0.91 | SGPL1 (0.58) | SGPL1S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL29472620 | 0.91 | SGPL1 (0.58) | SGPL1S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL17522136 | 0.91 | SGPL1 (0.58) | SGPL1S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL8934971 | 0.85 | SGPL1 (0.66) | SGPL1PLA2G4ALPAR5PTPN1LPAR6 | |
| SCHEMBL13030814 | 0.85 | SGPL1 (0.66) | SGPL1PLA2G4ALPAR5PTPN1LPAR6 | |
| SCHEMBL861987 | 0.83 | SGPL1 (0.63) | SGPL1PLA2G4ALPAR5PTPN1LPAR6 | |
| SCHEMBL1273298 | 0.83 | SGPL1 (0.63) | SGPL1PLA2G4ALPAR5PTPN1LPAR6 | |
| SCHEMBL21428471 | 0.81 | S1PR2 (0.67) | SGPL1S1PR1S1PR3S1PR2S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3907510-B1 | BIOCHEMICAL DIAGNOSTIC TEST FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | UNIV PONTIFICIA CATOLICA CHILE (CL) | 2025-03-26 | — | — | EP | claimed |
| WO-2024189238-A1 | BIOMARKERS DISCRIMINATING PHENOTYPES OF X-ADRENOLEUKODYSTROPHY | INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (ES) | 2024-09-19 | — | — | WO | claimed |
| CN-117500785-A | Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-02-02 | — | — | CN | claimed |
| US-20230410977-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES | 2023-12-21 | — | — | US | claimed |
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | claimed |
| EP-4228667-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | Brightseed, Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| CN-111505099-B | Diagnostic markers for NASH and uses thereof | 上海市普陀区中心医院 | 2023-07-04 | — | — | CN | claimed |
| EP-4192881-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| CN-113624862-B | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2023-04-07 | — | — | CN | claimed |
| CN-113295793-B | Biomarker for predicting early diabetes and diabetes occurrence, detection method and application thereof | 复旦大学附属中山医院 | 2022-11-04 | — | — | CN | claimed |
| EP-4069210-A1 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | Dyve Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| US-20220265713-A1 | SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-08-25 | — | — | US | claimed |
| WO-2022140565-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES (US) | 2022-06-30 | — | — | WO | claimed |
| EP-3986417-A1 | SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS | Deutsches Krebsforschungszentrum (DE) | 2022-04-27 | — | — | EP | claimed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| US-20220082576-A1 | BIOCHEMICAL DIAGNOSTIC TEST FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | UNIV PONTIFICIA CATOLICA CHILE (CL) | 2022-03-17 | — | — | US | claimed |
| WO-2022032293-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20070148168-A1 | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions | LPATH, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007053447-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY AND NEOVASCULARIZATION CONDITIONS | LPATH, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265713-A1 | SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS | CD4, S1PR1, S1PR2 | SGPL1 17/4885S1PR1 2/4885S1PR3 4/4885 |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | SGPL1 12/4885S1PR1 3/4885S1PR3 2/4885 |
| US-20070148168-A1 | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions | S1PR1, S1PR5, S1PR3 | SGPL1 15/4885S1PR1 1/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.